Pneumomediastinum, pneumopericardium pneumothorax and subcutaneous emphysema in Iranian COVID-19 patients

Abstract

Recently, spontaneous pneumomediastinum (PM), pneumopericardium (PP), pneumothorax (PT), and subcutaneous emphysema (SE) were reported as infrequent complications in coronavirus disease 2019 (COVID-19) patients in intensive care (ICU). Here we report these complications in nine Iranian patients of COVID-19. Nine patients with reported PM, PP, PT, and SE in COVID-19 who were hospitalized in Arya hospital, Rasht, Iran, for three months, were followed to record demographic data and clinical characteristics of these patients. In nine PM-developed patients, six cases represented PT, one patient with PP, and four patients with PT and SE. Four patents expired and only five patients survived. PM, PP, PT, and SE are uncommon complications in COVID-19 patients and were reported frequently in male patients. Early diagnosis and treatment could save the patients since these complications are related to poor prognosis and prolonged hospitalization. Patients with mild COVID-19 and mild pulmonary damage have a favorable outcome.

Association of MicroRNA-146a with Type 1 and 2 Diabetes and their Related Complications

“…Patients with COVID-19. Nowadays, the pandemic of coronavirus disease-2019 (COVID-19) is a serious hazard for the healthcare system and patients with primary diseases [62][63][64][65][66][67][68]. It has been revealed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections has the ability to lead to an increased host immune system response and severity of multiple diseases, such as diabetes, hypertension, cardiovascular, and neurological complications [69][70][71][72][73].…”

Purinergic P2X7 Receptor as a Potential Targeted Therapy for COVID-19-associated Lung Cancer Progression

“…COVID-19, which emerged in Dec 2019, has caused a concerning epidemic worldwide by SARS-CoV-2 [1][2][3][4][5]. Glycoprotein S or spike protein is the main contributor to virus entry into the host cells and its infection through binding to angiotensin-converting enzyme 2 (ACE2) receptor [6].…”

Hypoxia‐inducible factor 1 alpha (HIF‐1α) stimulated and P2X7 receptor activated by COVID-19, as a potential therapeutic target and risk factor for epilepsy

“…Coronavirus Disease 2019 (COVID-19) is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and affects billions of people around the world [ 1 – 7 ]. SARS-CoV-2 has been increasingly reported to attack not only the respiratory system and lead to respiratory complications [ 8 ] but also the central nervous system (CNS), causing neurological symptoms [ 9 – 12 ], and progression of multiple cancers [ 13 , 14 ]. According to retrospective investigations, 36.4% of SARS-CoV-2-infected individuals presented neurological manifestations such as acute cerebrovascular diseases, disturbed consciousness, and paresthesia [ 15 ].…”